Questions.
Direct answers.

PharmaBrandX is a pharma & medtech branding and communication agency for pharmaceutical companies, medtech firms, API makers and distributors. It combines three connected services: branding, reviewed communication, reputation. Brand systems, approved product information and B2B communication for pharma and medtech teams. Build clarity around evidence, intended use and responsible review.

Proposed starting fees are ₹40,000 one-time for Diagnose the problem, ₹65,000 one-time for Fix my claim-approval workflow, and ₹1,20,000 per month for Operate & improve. These are planning fees, not binding quotations; taxes, media spend and third-party costs are extra unless agreed.

PharmaBrandX works with pharma manufacturers, medtech companies, distributors, life-science services. Each business type starts from a different brief: for example, pharma manufacturers need claim registers, review ownership and controlled templates.

A first phase typically follows a 90-day rhythm: days 1–30 clarify the brief and establish direction, days 31–60 connect the page, content and handoff, and days 61–90 review evidence and decide the next phase. Exact timing depends on scope, asset readiness and approvals.

Review of your agreed records and current customer journey; Customer questions, objections and alternatives reviewed; A baseline for approval turnaround and unsupported claims caught; Positioning and messaging recommendation; An evidence-backed diagnosis: priorities and what can wait; A clear, written scope for the fix. Scope, inputs and timing are agreed in writing first.

No. Reviews are requested neutrally and never purchased or incentivised, and no ranking, enquiry or revenue outcome is guaranteed. The work focuses on accurate information, a useful customer journey and a responsible response process.

Yes—content and first ideas you can generate yourself with AI. That is not the main value of the service. We learn how your business actually works, then connect the right message, real information, a working enquiry process and team follow-up, and check against agreed records what improved. If you only need files, the scope is different. If you need a customer journey that is implemented and maintained, that is what we do.

The action that matters for pharma & medtech: an approved, traceable publication. Reporting follows the chain Approval turnaround → Unsupported claims caught → Outdated assets corrected—not impressions or form counts alone. Linking a result to a campaign is not proof the campaign caused it, so comparison periods and data limits are explained.

Prescription medicines should not be promoted to the public, and certain disease claims are prohibited outright. Corporate information, capabilities and approved product information for professionals are possible with medical and regulatory review.

The Uniform Code for Pharmaceutical Marketing Practices sets expectations for how pharmaceutical companies promote products and engage healthcare professionals, including evidence-based claims and restrictions on gifts and hospitality.

Fix the gap closest to the customer’s decision. If people cannot tell what you offer, start with brand clarity. If they understand but do not act, improve the customer journey from define to explain. If they hesitate because of trust, start with information accuracy and feedback handling. The free project planner recommends a starting point in five questions.

Only when the existing positioning or identity is part of the problem. A scoped review can recommend keeping working assets and improving a specific journey instead.

Accurate business information, approved images, access to relevant accounts, a named reviewer and a contact owner. For pharma & medtech, this also includes evidence and permissions for any professional or product claims.

Yes. The engagement can be scoped around a gap rather than replacing a team. Responsibilities, access and approvals are agreed before work begins.

The agreed deliverables, coverage, revisions and reporting are documented. Advertising spend, software, shoots, custom development and specialist reviews are not assumed to be included.

No. We commit to an agreed scope, test the journey and report the available evidence. Demand, pricing, competition, client response and the actual service experience affect business results.

Client accounts should remain client-owned, with role-based access. Final agreed assets and a handover record are included; third-party licences and working-file scope are documented.

Typical deliverables are corporate and product hierarchy, evidence-friendly visual system, approved product template library, technical presentation design. The exact quantities, revisions and handover are fixed in the statement of work before work begins.

Work usually starts with Diagnose the problem (from ₹40,000), which confirms whether branding is the real priority. A final quotation follows the scope agreement.

Typical deliverables are reviewed b2b product content, intended-use information design, trade and distributor enquiry journeys, approved event and exhibition materials. The exact quantities, revisions and handover are fixed in the statement of work before work begins.

Work usually starts with Diagnose the problem (from ₹40,000), which confirms whether reviewed communication is the real priority. The closest engagement, Fix my claim-approval workflow, has a proposed starting fee of ₹65,000 one-time. A final quotation follows the scope agreement.

Typical deliverables are claim and version register, medical and regulatory approval workflow, public-information correction process, inquiry and complaint escalation. The exact quantities, revisions and handover are fixed in the statement of work before work begins.

Work usually starts with Diagnose the problem (from ₹40,000), which confirms whether reputation is the real priority. The closest engagement, Operate & improve, has a proposed starting fee of ₹1,20,000 per month. A final quotation follows the scope agreement.